CHICAGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Pathos AI, Inc. (www.pathos.com), a biotechnology company focused on revolutionizing precision medicine in cancer by harnessing the power of machine learning ...
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, today announced its $365 million Series D ...
CHICAGO--(BUSINESS WIRE)--Pathos AI, Inc. (“Pathos”) today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. (“Merger Sub”), successfully completed its tender offer to ...
Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding. The company didn’t disclose the ...
CHICAGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Pathos AI, a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, today announced the closing of ...
Rain Oncology (NASDAQ:RAIN) has agreed to be acquired by Pathos AI for $1.16, per share in cash and a potential cash payments of up to approximately $0.17 per share. Based in Newark, California the ...
AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and comprehensive generative artificial intelligence model for oncology. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results